E2F1 inhibition mediates cell death of metastatic melanoma

Melanoma is one of the most lethal cancers when it reaches a metastatic stage. Despite advancements in targeted therapies (BRAF inhibitors) or immunotherapies (anti-CTLA-4 or anti-PD1), most patients with melanoma will need additional treatment. Thus, there is an urgent need to develop new therapeut...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cell Death Dis
Asıl Yazarlar: Rouaud, Florian, Hamouda-Tekaya, Nedra, Cerezo, Michaël, Abbe, Patricia, Zangari, Joséphine, Hofman, Veronique, Ohanna, Mickaël, Mograbi, Baharia, El-Hachem, Najla, Benfodda, Zohra, Lebeau, Alexandre, Tulic, Meri K., Hofman, Paul, Bertolotto, Corine, Passeron, Thierry, Annicotte, Jean-Sébastien, Ballotti, Robert, Rocchi, Stéphane
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5943238/
https://ncbi.nlm.nih.gov/pubmed/29743521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0566-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller